Technical Analysis for XCUR - Exicure, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.71 | -0.58% | -0.01 |
Earnings due: May 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical XCUR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | -0.58% | |
Wide Bands | Range Expansion | -0.58% | |
Oversold Stochastic | Weakness | -0.58% | |
Spinning Top | Other | 2.40% | |
Lower Bollinger Band Walk | Weakness | 2.40% | |
Wide Bands | Range Expansion | 2.40% | |
Below Lower BB | Weakness | 2.40% | |
Down 3 Days in a Row | Weakness | 2.40% | |
Down 4 Days in a Row | Weakness | 2.40% | |
Down 5 Days in a Row | Weakness | 2.40% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 1 hour ago |
60 Minute Opening Range Breakdown | about 2 hours ago |
Down 2 % | about 2 hours ago |
60 Minute Opening Range Breakout | about 5 hours ago |
Rose Above Previous Day's High | about 5 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/01/2021
Exicure, Inc. Description
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Mild Messenger RNA Oncology Applications Netherton Syndrome Purdue Pharma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.3 |
52 Week Low | 1.38 |
Average Volume | 614,309 |
200-Day Moving Average | 2.03 |
50-Day Moving Average | 2.24 |
20-Day Moving Average | 2.01 |
10-Day Moving Average | 1.86 |
Average True Range | 0.14 |
ADX | 29.09 |
+DI | 11.62 |
-DI | 31.87 |
Chandelier Exit (Long, 3 ATRs ) | 2.22 |
Chandelier Exit (Short, 3 ATRs ) | 2.05 |
Upper Bollinger Band | 2.37 |
Lower Bollinger Band | 1.65 |
Percent B (%b) | 0.1 |
BandWidth | 35.67 |
MACD Line | -0.15 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.0383 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.87 | ||||
Resistance 3 (R3) | 1.87 | 1.81 | 1.85 | ||
Resistance 2 (R2) | 1.81 | 1.78 | 1.82 | 1.84 | |
Resistance 1 (R1) | 1.77 | 1.75 | 1.79 | 1.77 | 1.83 |
Pivot Point | 1.71 | 1.71 | 1.73 | 1.72 | 1.71 |
Support 1 (S1) | 1.67 | 1.68 | 1.69 | 1.67 | 1.61 |
Support 2 (S2) | 1.61 | 1.65 | 1.62 | 1.60 | |
Support 3 (S3) | 1.57 | 1.61 | 1.60 | ||
Support 4 (S4) | 1.57 |